Incyte Corp INCY:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:15 PM EDT
65.45quote price arrow down-0.02 (-0.03%)
Volume
63,891
Close
65.47quote price arrow up+0.89 (+1.38%)
Volume
1,094,302
52 week range
64.08 - 101.47
Loading...
  • Open64.69
  • Day High65.68
  • Day Low64.57
  • Prev Close64.58
  • 52 Week High101.47
  • 52 Week High Date01/25/21
  • 52 Week Low64.08
  • 52 Week Low Date10/13/21

Key Stats

  • Market Cap14.458B
  • Shares Out220.84M
  • 10 Day Average Volume1.69M
  • Dividend-
  • Dividend Yield-
  • Beta0.78
  • YTD % Change-24.73

KEY STATS

  • Open64.69
  • Day High65.68
  • Day Low64.57
  • Prev Close64.58
  • 52 Week High101.47
  • 52 Week High Date01/25/21
  • 52 Week Low64.08
  • 52 Week Low Date10/13/21
  • Market Cap14.458B
  • Shares Out220.84M
  • 10 Day Average Volume1.69M
  • Dividend-
  • Dividend Yield-
  • Beta0.78
  • YTD % Change-24.73

RATIOS/PROFITABILITY

  • EPS (TTM)1.53
  • P/E (TTM)42.85
  • Fwd P/E (NTM)20.00
  • EBITDA (TTM)532.205M
  • ROE (TTM)12.79%
  • Revenue (TTM)2.721B
  • Gross Margin (TTM)95.72%
  • Net Margin (TTM)12.41%
  • Debt To Equity (MRQ)1.17%

EVENTS

  • Earnings Date11/02/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia...
Herve Hoppenot
Chairman
Christiana Stamoulis
Chief Financial Officer
Maria Pasquale J.D.
Executive Vice President
Paula Swain
Executive Vice President
Michael Morrissey
Executive Vice President
Address
1801 Augustine Cut off
Wilmington, DE
19803-4404
United States

Top Peers

SYMBOLLASTCHG%CHG
CRL
Charles River Laboratories International Inc
412.52-1.49-0.36%
EXAS
Exact Sciences Corp
96.52+0.69+0.72%
NVZMY
Novozymes A/S
69.96+0.41+0.59%
NVAX
Novavax Inc
160.55-5.70-3.43%
NBIX
Neurocrine Biosciences Inc
103.13-0.89-0.86%